HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 201 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.47 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $25,129,000 | +25.9% | 479,932 | -2.2% | 0.01% | +20.0% |
Q1 2024 | $19,960,000 | +8.1% | 490,665 | -1.8% | 0.01% | +25.0% |
Q4 2023 | $18,468,000 | +0.3% | 499,701 | +3.6% | 0.00% | -20.0% |
Q3 2023 | $18,420,000 | -0.8% | 482,246 | -6.3% | 0.01% | 0.0% |
Q2 2023 | $18,560,000 | -3.6% | 514,547 | +2.1% | 0.01% | 0.0% |
Q1 2023 | $19,244,000 | -10.6% | 503,926 | +33.1% | 0.01% | -16.7% |
Q4 2022 | $21,535,000 | +27.9% | 378,466 | -11.1% | 0.01% | +20.0% |
Q3 2022 | $16,842,000 | +1448.0% | 425,952 | +1622.6% | 0.01% | – |
Q2 2022 | $1,088,000 | +83.5% | 24,727 | +66.3% | 0.00% | – |
Q1 2022 | $593,000 | -88.2% | 14,873 | -88.1% | 0.00% | -100.0% |
Q4 2021 | $5,026,000 | +218.5% | 125,010 | +222.2% | 0.00% | – |
Q3 2021 | $1,578,000 | -15.0% | 38,802 | -5.0% | 0.00% | – |
Q2 2021 | $1,856,000 | -39.7% | 40,847 | -44.7% | 0.00% | -100.0% |
Q1 2021 | $3,079,000 | +325.9% | 73,847 | +335.7% | 0.00% | – |
Q4 2020 | $723,000 | -17.3% | 16,950 | -49.1% | 0.00% | – |
Q3 2020 | $874,000 | -65.0% | 33,294 | -64.2% | 0.00% | -100.0% |
Q2 2020 | $2,496,000 | +316.0% | 93,085 | +179.4% | 0.00% | – |
Q1 2020 | $600,000 | +152.1% | 33,314 | +148.3% | 0.00% | – |
Q4 2019 | $238,000 | +1152.6% | 13,419 | +999.9% | 0.00% | – |
Q3 2019 | $19,000 | -9.5% | 1,220 | -3.6% | 0.00% | – |
Q2 2019 | $21,000 | -4.5% | 1,266 | -7.6% | 0.00% | – |
Q1 2019 | $22,000 | -12.0% | 1,370 | -20.7% | 0.00% | – |
Q4 2018 | $25,000 | -67.1% | 1,727 | -58.7% | 0.00% | – |
Q3 2018 | $76,000 | -74.8% | 4,178 | -76.6% | 0.00% | – |
Q2 2018 | $301,000 | +584.1% | 17,882 | +688.8% | 0.00% | – |
Q1 2018 | $44,000 | -37.1% | 2,267 | -34.1% | 0.00% | – |
Q4 2017 | $70,000 | -72.7% | 3,441 | -76.7% | 0.00% | – |
Q3 2017 | $256,000 | +383.0% | 14,746 | +258.6% | 0.00% | – |
Q2 2017 | $53,000 | -75.7% | 4,112 | -75.6% | 0.00% | – |
Q1 2017 | $218,000 | +17.2% | 16,818 | -10.2% | 0.00% | – |
Q4 2016 | $186,000 | -81.1% | 18,736 | -77.0% | 0.00% | -100.0% |
Q3 2016 | $985,000 | +707.4% | 81,500 | +473.9% | 0.00% | – |
Q2 2016 | $122,000 | +3.4% | 14,200 | +13.5% | 0.00% | – |
Q1 2016 | $118,000 | -86.2% | 12,515 | -74.7% | 0.00% | -100.0% |
Q4 2015 | $857,000 | +20.9% | 49,469 | -6.4% | 0.00% | 0.0% |
Q3 2015 | $709,000 | -71.8% | 52,828 | -52.5% | 0.00% | -50.0% |
Q2 2015 | $2,510,000 | +155.3% | 111,118 | +61.5% | 0.00% | +100.0% |
Q1 2015 | $983,000 | +216.1% | 68,816 | +113.7% | 0.00% | – |
Q4 2014 | $311,000 | -83.6% | 32,200 | -84.6% | 0.00% | -100.0% |
Q3 2014 | $1,902,000 | +141.7% | 209,000 | +162.2% | 0.00% | – |
Q2 2014 | $787,000 | +54.0% | 79,700 | +98.3% | 0.00% | – |
Q1 2014 | $511,000 | -71.4% | 40,200 | -66.3% | 0.00% | -100.0% |
Q4 2013 | $1,787,000 | +225.5% | 119,200 | +139.4% | 0.00% | – |
Q3 2013 | $549,000 | +175.9% | 49,792 | +99.4% | 0.00% | – |
Q2 2013 | $199,000 | – | 24,969 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |